AMPH - Company ID 0001297184
The table below shows Amphastar Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $171.17M | $191.84M | $174.41M | $170.53M | $191.21M | $182.39M |
| Cost of revenue | $100.85M | $93.19M | $87.92M | $85.28M | $89.27M | $87.23M |
| Gross profit | $70.32M | $98.65M | $86.49M | $85.25M | $101.94M | $95.17M |
| R&D | $26.74M | $22.35M | $20.08M | $20.10M | $21.08M | $17.65M |
Amphastar Pharmaceuticals, Inc. reported annual revenue of $719.89M for fiscal year 2025. That is down 1.7% from $731.97M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $255.16M (FY 2016) to $719.89M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $18.03M | $39.47M | $13.99M | $16.00M | $14.82M | $13.29M |
| Operating income | $13.63M | $25.32M | $42.18M | $37.29M | $57.05M | $55.22M |
| Income tax | $3.63M | $4.16M | $8.30M | $5.58M | $7.25M | $12.29M |
| Net income | $6.42M | $17.35M | $31.03M | $25.29M | $40.43M | $37.95M |
| EPS (diluted) | $0.14 | $0.37 | $0.64 | $0.51 | $0.78 | $0.73 |